RPG Life Sciences reported a notable 8.3% increase in revenue for FY26, reaching INR 707.5 crores. The company's domestic formulation growth significantly outpaced the Indian pharma market, achieving a 1.6x expansion. EBITDA margin was maintained at 24.4%.

RPG Life Sciences has experienced a significant breakout, marked by a strong bullish trend. The stock's upward trajectory is evident in its series of higher highs and higher lows, indicating growing bullish momentum.

RPG Life Sciences has seen a 24% increase in Q4 revenue, reaching INR 176.9 crores. The company is now focusing on global expansion and introducing new products in the upcoming fiscal year.

NK Securities has offloaded approximately 109,801 shares of RPG Life Sciences, with an average sale price of around INR 2,259 per share on the National Stock Exchange.

RPG Life Sciences presented its Q4 FY26 results, showcasing superior market performance. Key priorities involve strengthening core brands, expanding specialty portfolios, pursuing global markets, and enhancing operational efficiency to drive growth.

RPG Life Sciences has scheduled a board meeting on the 29th of April, 2026 to announce their Q4 financial results for stakeholder review.

Despite facing industry-wide difficulties, RPG Life Sciences now boasts an appealing valuation due to reduced share prices. Improved Price-to-Earnings (P/E) and Price-to-Book Value (P/BV) ratios make it an enticing investment option within the sector.